Comparison of drug coverage in Canada before and after the establishment of the pan-Canadian Pharmaceutical Alliance
Objectives This study was conducted to determine whether establishment of the pan-Canadian Pharmaceutical Alliance (pCPA) was associated with significant changes in drug listing decisions across Canada. Analysis and results This study included drug indications that received a Common Drug Review or p...
Published in: | BMJ Open |
---|---|
Main Authors: | , , , , , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
BMJ
2015
|
Subjects: | |
Online Access: | http://dx.doi.org/10.1136/bmjopen-2015-008100 https://syndication.highwire.org/content/doi/10.1136/bmjopen-2015-008100 |
id |
crjcrbmj:10.1136/bmjopen-2015-008100 |
---|---|
record_format |
openpolar |
spelling |
crjcrbmj:10.1136/bmjopen-2015-008100 2024-06-23T07:54:48+00:00 Comparison of drug coverage in Canada before and after the establishment of the pan-Canadian Pharmaceutical Alliance Milliken, Debbie Venkatesh, Jaya Yu, Rebecca Su, Zhuo Thompson, Melissa Eurich, Dean 2015 http://dx.doi.org/10.1136/bmjopen-2015-008100 https://syndication.highwire.org/content/doi/10.1136/bmjopen-2015-008100 en eng BMJ BMJ Open volume 5, issue 9, page e008100 ISSN 2044-6055 2044-6055 journal-article 2015 crjcrbmj https://doi.org/10.1136/bmjopen-2015-008100 2024-05-30T08:18:59Z Objectives This study was conducted to determine whether establishment of the pan-Canadian Pharmaceutical Alliance (pCPA) was associated with significant changes in drug listing decisions across Canada. Analysis and results This study included drug indications that received a Common Drug Review or pan-Canadian Oncology Drug Review listing recommendation within 3 years before (‘pre-PCPA era’ group; n=79) and 3 years after (‘PCPA era’ group; n=91) the pCPA was established in August 2010. At the time of this study (30 April 2014), nine pCPA-participating jurisdictions had listed 35–59% of drug indications in the pre-pCPA era group and a nearly identical range, 36–59%, in the pCPA era group. Within the pCPA-era group, 31 drug indications (34%) had completed pCPA negotiations (‘pCPA negotiation’ subgroup); the jurisdictions had listed 39–77% of these drug indications. Comparison of the pCPA era group to the pre-pCPA era group indicated that the proportion listed did not change significantly in any jurisdiction, and time-to-listing increased significantly in New Brunswick and decreased significantly in Alberta, Manitoba, and Ontario. When the pCPA negotiation subgroup was compared to the pre-pCPA era group, the proportion listed increased significantly in British Columbia, Saskatchewan, Manitoba and Newfoundland and Labrador, and time-to-listing increased significantly in New Brunswick and Nova Scotia and decreased significantly in Manitoba and Ontario. A sensitivity analysis suggested more favourable results regarding the pCPA's impact. Conclusions While the pCPA might have had a varied effect on time-to-listing, this study's primary analysis did not observe a significant impact on the overall proportion of new drug indications listed across jurisdictions. This may be due to the fact that, at the time of this study, only a limited number of drug indications had completed pCPA negotiations. This study provides a framework for future evaluations of the pCPA's impact as it continues to evolve. Article in Journal/Newspaper Newfoundland The BMJ British Columbia ENVELOPE(-125.003,-125.003,54.000,54.000) Canada Newfoundland BMJ Open 5 9 e008100 |
institution |
Open Polar |
collection |
The BMJ |
op_collection_id |
crjcrbmj |
language |
English |
description |
Objectives This study was conducted to determine whether establishment of the pan-Canadian Pharmaceutical Alliance (pCPA) was associated with significant changes in drug listing decisions across Canada. Analysis and results This study included drug indications that received a Common Drug Review or pan-Canadian Oncology Drug Review listing recommendation within 3 years before (‘pre-PCPA era’ group; n=79) and 3 years after (‘PCPA era’ group; n=91) the pCPA was established in August 2010. At the time of this study (30 April 2014), nine pCPA-participating jurisdictions had listed 35–59% of drug indications in the pre-pCPA era group and a nearly identical range, 36–59%, in the pCPA era group. Within the pCPA-era group, 31 drug indications (34%) had completed pCPA negotiations (‘pCPA negotiation’ subgroup); the jurisdictions had listed 39–77% of these drug indications. Comparison of the pCPA era group to the pre-pCPA era group indicated that the proportion listed did not change significantly in any jurisdiction, and time-to-listing increased significantly in New Brunswick and decreased significantly in Alberta, Manitoba, and Ontario. When the pCPA negotiation subgroup was compared to the pre-pCPA era group, the proportion listed increased significantly in British Columbia, Saskatchewan, Manitoba and Newfoundland and Labrador, and time-to-listing increased significantly in New Brunswick and Nova Scotia and decreased significantly in Manitoba and Ontario. A sensitivity analysis suggested more favourable results regarding the pCPA's impact. Conclusions While the pCPA might have had a varied effect on time-to-listing, this study's primary analysis did not observe a significant impact on the overall proportion of new drug indications listed across jurisdictions. This may be due to the fact that, at the time of this study, only a limited number of drug indications had completed pCPA negotiations. This study provides a framework for future evaluations of the pCPA's impact as it continues to evolve. |
format |
Article in Journal/Newspaper |
author |
Milliken, Debbie Venkatesh, Jaya Yu, Rebecca Su, Zhuo Thompson, Melissa Eurich, Dean |
spellingShingle |
Milliken, Debbie Venkatesh, Jaya Yu, Rebecca Su, Zhuo Thompson, Melissa Eurich, Dean Comparison of drug coverage in Canada before and after the establishment of the pan-Canadian Pharmaceutical Alliance |
author_facet |
Milliken, Debbie Venkatesh, Jaya Yu, Rebecca Su, Zhuo Thompson, Melissa Eurich, Dean |
author_sort |
Milliken, Debbie |
title |
Comparison of drug coverage in Canada before and after the establishment of the pan-Canadian Pharmaceutical Alliance |
title_short |
Comparison of drug coverage in Canada before and after the establishment of the pan-Canadian Pharmaceutical Alliance |
title_full |
Comparison of drug coverage in Canada before and after the establishment of the pan-Canadian Pharmaceutical Alliance |
title_fullStr |
Comparison of drug coverage in Canada before and after the establishment of the pan-Canadian Pharmaceutical Alliance |
title_full_unstemmed |
Comparison of drug coverage in Canada before and after the establishment of the pan-Canadian Pharmaceutical Alliance |
title_sort |
comparison of drug coverage in canada before and after the establishment of the pan-canadian pharmaceutical alliance |
publisher |
BMJ |
publishDate |
2015 |
url |
http://dx.doi.org/10.1136/bmjopen-2015-008100 https://syndication.highwire.org/content/doi/10.1136/bmjopen-2015-008100 |
long_lat |
ENVELOPE(-125.003,-125.003,54.000,54.000) |
geographic |
British Columbia Canada Newfoundland |
geographic_facet |
British Columbia Canada Newfoundland |
genre |
Newfoundland |
genre_facet |
Newfoundland |
op_source |
BMJ Open volume 5, issue 9, page e008100 ISSN 2044-6055 2044-6055 |
op_doi |
https://doi.org/10.1136/bmjopen-2015-008100 |
container_title |
BMJ Open |
container_volume |
5 |
container_issue |
9 |
container_start_page |
e008100 |
_version_ |
1802647078484049920 |